Food recall analysis finds 196 of 506 FDA recalls are Class I
The announcement opens by citing USDA estimates that place the annual U.S. foodborne illness economic burden at $74.7 billion while introducing the H&P Law analysis of federal recall activity. USDA data indicate 47.8 million illnesses occur each year in 2023 dollars. The announcement notes that 31 major pathogens account for roughly 20 percent of cases yet drive about 60 percent of total costs. H&P Law examined 506 FDA recall events from 2025 and found 196 involved at least one Class I product. The announcement places these recall figures against the broader economic picture without assigning direct shares of the $74.7 billion burden to specific recall hazards.
The announcement details cost concentration between the 31 major pathogens and remaining gastroenteritis cases. The 31 pathogens produced 9,388,133 estimated illnesses, $44.74 billion in annual economic cost, and a mean cost per case of $4,766. Other foodborne gastroenteritis accounted for 38,392,704 illnesses, $29.97 billion in cost, and a mean of $781 per case. National totals reached 47,780,837 illnesses, $74.72 billion, and $1,564 mean cost per case. These measures encompass medical care, lost productivity, and premature death rather than recall expenses alone.
The announcement presents the five costliest pathogens among the 31 with their annual cases, economic costs, and mean costs per case. Nontyphoidal Salmonella recorded 1,027,561 cases, $17.13 billion, and $16,668 per case. Campylobacter recorded 845,024 cases, $11.33 billion, and $13,405 per case. Toxoplasma gondii recorded 86,753 cases, $5.72 billion, and $65,926 per case. Listeria monocytogenes recorded 1,583 cases, $3.96 billion, and $2,504,296 per case. Norovirus recorded 5,461,731 cases, $2.97 billion, and $543 per case.
The announcement explains that most costs arise from severe illnesses such as listeriosis despite low case counts and incorporates long-term health effects. The 31 major pathogens cause about 20 percent of cases but about 60 percent of the economic burden. Long-term effects add roughly $23.4 billion. Listeria illustrates the pattern with only 1,583 cases yet a mean cost exceeding $2.5 million per case. The figures cover medical care, lost productivity, and premature death and are not limited to hospital bills or recall costs.
The announcement reports H&P Law findings on 2025 FDA recalls, including the Class I proportion and leading hazards. Of 506 events, 196 or 38.7 percent involved at least one Class I product. Undeclared allergens appeared in 181 events or 35.8 percent. Foreign materials appeared in 68 events or 13.4 percent. Listeria appeared in 61 events or 12.1 percent. The announcement states that recall counts measure different outcomes from illness costs and cannot be apportioned against the $74.7 billion total.
The announcement covers the GAO January 2026 report on FDA Food Safety Modernization Act implementation and accountability gaps. GAO found FDA completed 41 of 46 requirements yet lacks a comprehensive process to assess whether the nine prevention rules reduce illness. Evaluation efforts centered mainly on compliance monitoring for three rules. HHS agreed with GAO's seven recommendations. The announcement notes the broader public health effect of the framework remains insufficiently assessed.
The announcement discusses broader federal food safety oversight involving multiple agencies and historical outbreak data. GAO documented 15 federal agencies administering at least 30 food safety laws. CDC data show more than 9,000 reported foodborne illness outbreaks between 2011 and 2022 spanning all 50 states. GAO has long recommended a national food safety strategy to address coordination, overlapping responsibilities, and consistent progress measures.
The announcement notes recent FDA draft guidance on traceability and an upcoming public meeting while stating that effects on illness rates remain unestablished. On October 8, 2026, FDA issued draft guidance proposing enforcement discretion for certain smaller retailers and restaurants under the Food Traceability Rule. FDA scheduled a public meeting on lot-level traceability for November 6 with written comments due December 6. The announcement indicates neither the guidance nor the meeting has established impacts on illness rates or costs.
